JNJ - Johnson & Johnson

NYSE - NYSE Delayed price. Currency in USD
139.20
-0.70 (-0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close139.90
Open139.65
Bid138.78 x 800
Ask139.15 x 800
Day's range138.86 - 140.14
52-week range118.62 - 148.99
Volume5,110,628
Avg. volume6,561,220
Market cap370.658B
Beta (3Y monthly)0.69
PE ratio (TTM)25.80
EPS (TTM)5.40
Earnings date16 Jul 2019
Forward dividend & yield3.60 (2.58%)
Ex-dividend date2019-02-25
1y target est145.44
Trade prices are not sourced from all markets
  • Reuters14 minutes ago

    India alleges big multinationals did not pass on tax benefits: source

    Indian tax authorities have alleged that a number of big multinational companies have not passed on benefits from a tax cut to customers, a senior government official told Reuters. The official said, for example, that the tax authorities have alleged that U.S. consumer goods maker Procter & Gamble did not pass on more than $35 million in tax benefits which were meant to have gone to its customers. Separately, the authorities are also investigating South Korea's Samsung Electronics and U.S. drug maker Johnson & Johnson among others, the senior government official, speaking on condition of anonymity, said.

  • Everything You Need to Know About Investing in Healthcare
    Motley Fool17 hours ago

    Everything You Need to Know About Investing in Healthcare

    The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.

  • Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
    Zacks20 hours ago

    Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

    Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

  • Exploring JNJ’s Key Oncology Assets in the First Quarter
    Market Realistyesterday

    Exploring JNJ’s Key Oncology Assets in the First Quarter

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in

  • Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1
    Market Realist2 days ago

    Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performanceIn the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide

  • Motley Fool2 days ago

    Prescription for Success?

    Prescription drug sales, the future of Hulu, and more.

  • JNJ’s Consumer Business: International Market Trends in Q1
    Market Realist2 days ago

    JNJ’s Consumer Business: International Market Trends in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC business performance in international markets In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY

  • JNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1
    Market Realist2 days ago

    JNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC businessIn the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported revenue of $1.09 billion, reflecting YoY

  • Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1
    Market Realist3 days ago

    Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performance In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide

  • What Are Analysts Recommending for Johnson & Johnson?
    Market Realist3 days ago

    What Are Analysts Recommending for Johnson & Johnson?

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Stock price movementsOn April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its

  • JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs
    Market Realist3 days ago

    JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on

  • JNJ Surpassed Consensus Estimates in the First Quarter
    Market Realist3 days ago

    JNJ Surpassed Consensus Estimates in the First Quarter

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?Revenue performance Johnson & Johnson (JNJ) reported its earnings results for the first quarter of 2019 on April 16. In its first-quarter earnings press release, the company

  • JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs
    Market Realist3 days ago

    JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of

  • JNJ or PFE: Which Has Better EPS Guidance for 2019?
    Market Realist3 days ago

    JNJ or PFE: Which Has Better EPS Guidance for 2019?

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) raised the guidance for its adjusted diluted operational EPS from its

  • Johnson & Johnson posts strong revenue in 1Q
    Associated Press4 days ago

    Johnson & Johnson posts strong revenue in 1Q

    Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant beat profit and revenue expectations, pushing up its ...

  • Asian shares edge lower despite encouraging China GDP data
    Associated Press4 days ago

    Asian shares edge lower despite encouraging China GDP data

    Major share benchmarks were mostly lower in Asia on Wednesday after China announced its economy grew at a 6.4% annual pace in the last quarter. Japan's Nikkei 225 index gained 0.3% to 22,289.32 and the ...

  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Fool6 days ago

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • Here Are the Key Takeaways From J&J's Q1 Earnings Report
    Zacks7 days ago

    Here Are the Key Takeaways From J&J's Q1 Earnings Report

    Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

  • Stock Market News For Apr 17, 2019
    Zacks8 days ago

    Stock Market News For Apr 17, 2019

    Markets closed higher on Tuesday as investors welcomed a spate of healthy first quarter earnings results.

  • Investing.com8 days ago

    StockBeat - UnitedHealth Deepens Losses as Fears Over Political Risk Rise

    Investing.com - UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO's warning on political risk.

  • 5 takeaways from Johnson & Johnson’s first-quarter results
    MarketWatch8 days ago

    5 takeaways from Johnson & Johnson’s first-quarter results

    Johnson & Johnson topped Wall Street’s earnings expectations on Tuesday, extending the company’s multiyear streak of delivering better-than-expected results.

  • Morningstar8 days ago

    Solid Drug Sales, Cost Control Boost Johnson & Johnson

    The first-quarter performance reinforces our wide moat rating.

  • Associated Press8 days ago

    US halts sales of pelvic mesh tied to injuries in women

    WASHINGTON (AP) — U.S. health regulators on Tuesday halted sales of a type of surgical mesh used to repair pelvic conditions in women, following years of patients' reports of injuries and complications from the implants.

  • Associated Press9 days ago

    Qualcomm and Progressive jump while Wave Life Sciences drops

    Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Corp., up $13.27 to $70.45 The mobile chip maker settled a long-running financial dispute with iPhone maker Apple. Johnson & Johnson, ...

  • What Happened in the Stock Market Today
    Motley Fool9 days ago

    What Happened in the Stock Market Today

    Johnson & Johnson's earnings results were better than expected, and UnitedHealth Group reported strong growth but stirred investor angst.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes